Vanda Pharmaceuticals, Inc. (VNDA) Posts Wider than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.22 +3.78%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q3 EPS of ($0.11), $0.03 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $8 million versus the consensus estimate of $8.26 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- This biotech stock offers a buying opportunity: B. Riley
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
